Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664057 | 1.00 | POLB (0.48) | POLBL3MBTL1HSD17B10ALDH1A1EPHX2 | |
| SCHEMBL667268 | 1.00 | POLB (0.48) | POLBL3MBTL1HSD17B10ALDH1A1EPHX2 | |
| SCHEMBL2749532 | 0.90 | HDAC8 (0.45) | POLBL3MBTL1ALDH1A1EPHX2MAPK1 | |
| SCHEMBL5110596 | 0.78 | L3MBTL1 (0.50) | POLBL3MBTL1ALDH1A1EPHX2MAPK1 | |
| SCHEMBL667136 | 0.77 | — | — | |
| SCHEMBL666297 | 0.77 | — | — | |
| SCHEMBL4490 | 0.77 | — | — | |
| SCHEMBL1489900 | 0.76 | MTNR1A (0.41) | MAPK1LMNAKDM5ATSHR | |
| SCHEMBL103961 | 0.74 | — | — | |
| SCHEMBL4999 | 0.73 | SMN1; SMN2 (0.35) | POLBALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | claimed |
| EP-2499144-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-10-23 | — | — | EP | claimed |
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-17 | — | — | US | claimed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | claimed |
| WO-2011058109-A1 | FUSED BICYCLIC PYRROLE AND IMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | claimed |
| WO-2011058111-A1 | AMINOPURINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | claimed |
| EP-1828223-A4 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1828223-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | Panacos Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006053255-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-8637543-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| EP-2499144-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-17 | — | — | US | disclosed |
| WO-2011058109-A1 | FUSED BICYCLIC PYRROLE AND IMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| EP-1828223-A4 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1828223-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | Panacos Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006053255-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, CDK3, MAP3K13 | POLB 1041/4885L3MBTL1 2556/4885HSD17B10 4522/4885 |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | POLB 1232/4885L3MBTL1 2807/4885HSD17B10 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.